8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Feb 24, 2026·SEC
Beam Therapeutics Inc.(BEAM)Earnings, Financials & Key Ratios
BEAM•NASDAQ
Price updated Jun 19, 2026
AboutBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.Show more
- Revenue$140M+120.0%
- EBITDA-$377M+4.1%
- Net Income-$80M+78.8%
- EPS (Diluted)-0.81+82.3%
- Gross Margin84.05%+117.6%
- EBITDA Margin-270.04%+56.4%
- Operating Margin-274.57%+58.0%
- Net Margin-57.24%+90.3%
- ROE-8.11%+81.5%
BEAM Key Insights
Beam Therapeutics Inc. (BEAM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 16.3%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 466.3%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 20.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BEAM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BEAM Price & Volume
Beam Therapeutics Inc. (BEAM) stock price & volume — 10-year historical chart
Loading chart...
BEAM Growth Metrics
Beam Therapeutics Inc. (BEAM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years466.27%
3 Years31.88%
TTM108.05%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM83.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM85.25%
Return on Capital
10 Years-42.74%
5 Years-32.71%
3 Years-28.78%
Last Year-33.28%
BEAM Recent Earnings
Beam Therapeutics Inc. (BEAM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.91-4.6%
$0.87
Rev
$32M+189.1%
$11M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.10+91.2%
$1.13
Rev
$114M+877.9%
$12M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$1.10-12.2%
$0.98
Rev
$10M-26.6%
$13M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$1.00+3.8%
$1.04
Rev
$8M-26.6%
$12M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.91vs $0.87-4.6% | $32Mvs $11M+189.1% |
| Q1 2026 | Feb 24, 2026 | $0.10vs $1.13+91.2% | $114Mvs $12M+877.9% |
| Q4 2025 | Nov 4, 2025 | $1.10vs $0.98-12.2% | $10Mvs $13M-26.6% |
| Q3 2025 | Aug 5, 2025 | $1.00vs $1.04+3.8% | $8Mvs $12M-26.6% |
Based on last 12 quarters of dataView full earnings history →
BEAM Peer Comparison
Beam Therapeutics Inc. (BEAM) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 PRME | 583.39M | 3.23 | -2.39 | 55.28% | -49.18% | -188.82% | 0.96 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 |
Compare BEAM vs Peers
Beam Therapeutics Inc. (BEAM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BEAM Income Statement
Beam Therapeutics Inc. (BEAM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 18K | 24K | 51.84M | 60.92M | 377.71M | 63.52M | 139.74M | 132.27M |
Revenue Growth % | - | - | - | 33.33% | 215916.67% | 17.51% | 520.01% | -83.18% | 120.01% | 108.05% |
Cost of Goods Sold | 0 | 33.87M | 54.62M | 103.18M | 232.13M | 311.59M | 0 | 367.56M | 22.29M | 217.19M |
COGS % of Revenue | - | - | 303438.89% | 429912.5% | 447.75% | 511.48% | - | 578.67% | 15.95% | - |
Gross Profit | 0▲ 0% | -33.87M▲ 0% | -54.6M▼ 61.2% | -103.16M▼ 88.9% | -180.29M▼ 74.8% | -250.67M▼ 39.0% | 377.71M▲ 250.7% | -304.04M▼ 180.5% | 117.45M▲ 138.6% | -84.92M▲ 0% |
Gross Margin % | - | - | -303338.89% | -429812.5% | -347.75% | -411.48% | 100% | -478.67% | 84.05% | -64.2% |
Gross Profit Growth % | - | - | -61.19% | -88.93% | -74.78% | -39.04% | 250.68% | -180.5% | 138.63% | - |
Operating Expenses | 8.6M | 11.87M | 20.55M | 29.6M | 212.18M | 87.81M | 554.19M | 111.53M | 501.14M | 318.44M |
OpEx % of Revenue | - | - | 114183.33% | 123354.16% | 409.26% | 144.13% | 146.73% | 175.58% | 358.62% | - |
Selling, General & Admin | 2.2M | 11.87M | 20.55M | 29.61M | 57.22M | 87.81M | 116.81M | 111.53M | 113.82M | 114.64M |
SG&A % of Revenue | - | - | 114183.33% | 123354.17% | 110.37% | 144.13% | 30.93% | 175.58% | 81.45% | - |
Research & Development | 5.86M | 33.87M | 54.62M | 103.18M | 387.09M | 311.59M | 437.38M | 367.56M | 409.62M | 415.33M |
R&D % of Revenue | - | - | 303438.89% | 429912.5% | 746.64% | 511.48% | 115.8% | 578.67% | 293.12% | - |
Other Operating Expenses | 0 | -33.87M | -54.62M | -103.18M | -232.13M | -311.59M | 0 | -367.56M | -22.29M | -2M |
Operating Income | -8.6M▲ 0% | -45.74M▼ 432.1% | -75.15M▼ 64.3% | -132.76M▼ 76.7% | -392.46M▼ 195.6% | -338.48M▲ 13.8% | -176.49M▲ 47.9% | -415.57M▼ 135.5% | -383.69M▲ 7.7% | -371.62M▲ 0% |
Operating Margin % | - | - | -417522.22% | -553166.66% | -757.01% | -555.61% | -46.73% | -654.25% | -274.57% | -280.95% |
Operating Income Growth % | - | -432.1% | -64.3% | -76.65% | -195.62% | 13.76% | 47.86% | -135.47% | 7.67% | - |
EBITDA | -8.58M | -45.09M | -71.65M | -128.03M | -385.01M | -324.33M | -146.95M | -393.64M | -377.36M | -354.86M |
EBITDA Margin % | - | - | -398061.11% | -533437.5% | -742.64% | -532.39% | -38.91% | -619.73% | -270.04% | -268.28% |
EBITDA Growth % | - | -425.27% | -58.9% | -78.68% | -200.73% | 15.76% | 54.69% | -167.87% | 4.14% | 13.17% |
D&A (Non-Cash Add-back) | 12K | 650K | 3.5M | 4.73M | 7.45M | 14.15M | 29.53M | 21.93M | 6.34M | 16.77M |
EBIT | -8.6M | -45.74M | -75.15M | -132.76M | -237.51M | -338.48M | -176.49M | -415.57M | -36.26M | 22.06M |
Net Interest Income | 0 | 0 | 2.3M | 1.57M | 0 | 0 | 0 | 49.09M | -43.73M | -9.6M |
Interest Income | 0 | 292K | 2.49M | 1.57M | 0 | 0 | 0 | 49.09M | 0 | 10.9M |
Interest Expense | 0 | 0 | 187K | 0 | 0 | 0 | 0 | 0 | 43.73M | 20.51M |
Other Income/Expense | -133.09K | -71M | -3.17M | -61.83M | 21.83M | 52.8M | 45.32M | 38.87M | 303.7M | 306.58M |
Pretax Income | -8.73M▲ 0% | -116.74M▼ 1237.3% | -78.33M▲ 32.9% | -194.59M▼ 148.4% | -370.64M▼ 90.5% | -285.68M▲ 22.9% | -131.16M▲ 54.1% | -376.7M▼ 187.2% | -79.99M▲ 78.8% | -65.04M▲ 0% |
Pretax Margin % | - | - | -435144.44% | -810800% | -714.91% | -468.94% | -34.73% | -593.07% | -57.24% | -49.17% |
Income Tax | 500K | 0 | 0 | 0 | 0 | 3.41M | 1.37M | 39K | 0 | 0 |
Effective Tax Rate % | -5.73% | 0% | 0% | 0% | 0% | -1.19% | -1.04% | -0.01% | 0% | 0% |
Net Income | -8.73M▲ 0% | -115.26M▼ 1220.3% | -78.33M▲ 32.0% | -194.59M▼ 148.4% | -370.64M▼ 90.5% | -289.09M▲ 22.0% | -132.53M▲ 54.2% | -376.74M▼ 184.3% | -79.99M▲ 78.8% | -65.04M▲ 0% |
Net Margin % | - | - | -435144.44% | -810800% | -714.91% | -474.54% | -35.09% | -593.13% | -57.24% | -49.17% |
Net Income Growth % | - | -1220.32% | 32.04% | -148.44% | -90.47% | 22% | 54.16% | -184.28% | 78.77% | 83.21% |
Net Income (Continuing) | -8.73M | -116.74M | -78.33M | -194.59M | -370.64M | -289.09M | -132.53M | -376.74M | -79.99M | -65.04M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.62▲ 0% | -3.28▼ 429.0% | -1.53▲ 53.4% | -5.49▼ 258.8% | -5.77▼ 5.1% | -4.13▲ 28.4% | -1.72▲ 58.4% | -4.58▼ 166.3% | -0.81▲ 82.3% | -0.63▲ 0% |
EPS Growth % | - | -429.03% | 53.35% | -258.82% | -5.1% | 28.42% | 58.35% | -166.28% | 82.31% | 85.25% |
EPS (Basic) | -0.62 | -3.28 | -1.53 | -5.49 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | - |
Diluted Shares Outstanding | 12.95M | 35.14M | 51.34M | 46.73M | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M | 103.26M |
Basic Shares Outstanding | 12.95M | 35.14M | 51.34M | 46.73M | 64.23M | 70.02M | 77.15M | 82.31M | 98.91M | 103.26M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BEAM Balance Sheet
Beam Therapeutics Inc. (BEAM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.04M | 148.28M | 94.54M | 308.32M | 1.27B | 1.09B | 1.21B | 878.15M | 1.27B | 1.27B |
Cash & Short-Term Investments | 1.9M | 146.44M | 91.85M | 299.67M | 965.65M | 1.08B | 1.19B | 850.74M | 1.25B | 1.21B |
Cash Only | 1.9M | 146.44M | 37.22M | 162.17M | 559.99M | 232.77M | 435.89M | 281.97M | 294.94M | 288.29M |
Short-Term Investments | 0 | 0 | 54.63M | 137.5M | 405.65M | 845.37M | 753.98M | 568.77M | 950.27M | 923.36M |
Accounts Receivable | 0 | 0 | 0 | 0 | 300M | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | 2.11K | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 14.76M | 21.17M | 27.41M | 0 | 55.3M |
Total Non-Current Assets | 365K | 18.74M | 61.55M | 143.36M | 201.45M | 248.82M | 248.67M | 225.68M | 212.49M | 213.84M |
Property, Plant & Equipment | 335K | 16.94M | 43.25M | 125.37M | 186.98M | 234.13M | 237.81M | 216.28M | 205.18M | 199.4M |
Fixed Asset Turnover | - | - | 0.00x | 0.00x | 0.28x | 0.26x | 1.59x | 0.29x | 0.68x | 0.65x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 30K | 1.49M | 0 | 0 | 0 | 0 | 0 | 0 | 6.68M | 6.68M |
Other Non-Current Assets | 0 | 300K | 18.31M | 17.98M | 14.47M | 14.69M | 10.87M | 9.4M | 634K | 14.45M |
Total Assets | 2.4M▲ 0% | 167.01M▲ 6853.0% | 156.1M▼ 6.5% | 451.68M▲ 189.4% | 1.47B▲ 226.4% | 1.34B▼ 9.0% | 1.46B▲ 8.8% | 1.1B▼ 24.4% | 1.48B▲ 34.2% | 1.48B▲ 0% |
Asset Turnover | - | - | 0.00x | 0.00x | 0.04x | 0.05x | 0.26x | 0.06x | 0.09x | 0.09x |
Asset Growth % | - | 6853.04% | -6.53% | 189.35% | 226.44% | -9% | 8.79% | -24.38% | 34.19% | 57.36% |
Total Current Liabilities | 6.57M | 25.59M | 29.14M | 102.34M | 213.44M | 223.59M | 205.56M | 182.07M | 96.94M | 74.56M |
Accounts Payable | 726K | 7.35M | 7.85M | 6.31M | 7.47M | 9.03M | 1.62M | 3.87M | 10.23M | 12.29M |
Days Payables Outstanding | - | 79.21 | 52.43 | 22.34 | 11.75 | 10.58 | - | 3.84 | 167.5 | 17.91 |
Short-Term Debt | 1.01M | 0 | 1.3M | 2.12M | 2.29M | 0 | 0 | 0 | 14.36M | 14.78M |
Deferred Revenue (Current) | -1.01M | 0 | 0 | 24K | 86.27M | 135.97M | 68.71M | 108.86M | 6.66M | 112.78M |
Other Current Liabilities | 4.7M | 16.54M | 12.56M | 83.02M | 60.83M | 49.68M | 100.69M | 19.74M | 36.34M | 47.19M |
Current Ratio | 0.31x | 5.79x | 3.24x | 3.01x | 5.96x | 4.89x | 5.89x | 4.82x | 13.09x | 16.99x |
Quick Ratio | 0.31x | 5.79x | 3.24x | 3.01x | 5.96x | 4.89x | 5.89x | 4.82x | 13.09x | 16.99x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 20K | 7.4M | 26.02M | 103.78M | 434.28M | 384.64M | 272.82M | 188.21M | 145.88M | 241.79M |
Long-Term Debt | 0 | 0 | 4.41M | 5.29M | 3.01M | 0 | 0 | 0 | 139.76M | 135.85M |
Capital Lease Obligations | 0 | 0 | 21.19M | 96.01M | 134.81M | 168.63M | 159.91M | 147.96M | 139.76M | 420.35M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20K | 7.4M | 418K | 2.08M | 34.16M | 13.84M | 3.02M | 7.04M | -133.63M | 105.95M |
Total Liabilities | 6.58M | 32.98M | 55.15M | 206.12M | 647.72M | 608.24M | 478.38M | 370.28M | 242.82M | 316.36M |
Total Debt | 1.01M | 0 | 31.24M | 107.64M | 147.64M | 179M | 172.69M | 161.43M | 293.88M | 150.63M |
Net Debt | -891K | -146.44M | -5.98M | -54.53M | -412.35M | -53.76M | -263.21M | -120.54M | -1.06M | -137.66M |
Debt / Equity | - | - | 0.31x | 0.44x | 0.18x | 0.24x | 0.18x | 0.22x | 0.24x | 0.13x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.42x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.39x |
Interest Coverage | - | - | -401.89x | - | - | - | - | - | -0.83x | 1.08x |
Total Equity | -4.18M▲ 0% | 134.03M▲ 3304.1% | 100.94M▼ 24.7% | 245.56M▲ 143.3% | 826.74M▲ 236.7% | 733.47M▼ 11.3% | 981.33M▲ 33.8% | 733.54M▼ 25.2% | 1.24B▲ 68.8% | 1.16B▲ 0% |
Equity Growth % | - | 3304.11% | -24.68% | 143.26% | 236.67% | -11.28% | 33.79% | -25.25% | 68.82% | 117.13% |
Book Value per Share | -0.32 | 3.81 | 1.97 | 5.25 | 12.87 | 10.48 | 12.72 | 8.91 | 12.52 | 11.28 |
Total Shareholders' Equity | -4.18M | 134.03M | 100.94M | 245.56M | 826.74M | 733.47M | 981.33M | 733.54M | 1.24B | 1.16B |
Common Stock | 5K | 56K | 73K | 573K | 684K | 712K | 816K | 836K | 1.02M | 1.03M |
Retained Earnings | -9.46M | -124.72M | -203.04M | -397.64M | -768.27M | -1.06B | -1.19B | -1.57B | -1.64B | -1.74B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -11K | -661K | 16K | -9K | -50K | -2.43M | 604K | 679K | 1.11M | -1.07M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BEAM Cash Flow Statement
Beam Therapeutics Inc. (BEAM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.71M | -20.3M | -72M | -95.74M | -66.27M | 22.53M | -149.19M | -347.25M | -345.1M | -369.73M |
Operating CF Margin % | - | - | -400016.67% | -398920.83% | -127.82% | 36.98% | -39.5% | -546.69% | -246.95% | - |
Operating CF Growth % | - | -649.83% | -254.73% | -32.97% | 30.78% | 133.99% | -762.29% | -132.75% | 0.62% | -17.33% |
Net Income | -8M | -116.74M | -78.33M | -194.59M | -370.64M | -289.09M | -132.53M | -376.74M | -79.99M | -65.04M |
Depreciation & Amortization | 11K | 650K | 3.5M | 4.74M | 7.45M | 14.15M | 20.01M | 21.93M | 22.29M | 22.37M |
Stock-Based Compensation | 198K | 7M | 7.03M | 15.38M | 43.57M | 84.32M | 98.65M | 120.66M | 94.24M | -26.68M |
Deferred Taxes | 500K | 11.75M | 0 | 63.52M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.85M | 66.96M | 6.5M | 9.87M | 142.09M | -38.48M | -18.87M | -2.87M | -250.63M | -139.22M |
Working Capital Changes | 740K | 10.07M | -10.71M | 5.35M | 111.25M | 251.63M | -116.45M | -110.22M | -131.02M | -161.16M |
Change in Receivables | 0 | 0 | 0 | 0 | -300M | 300M | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -300M | 0 | 0 | 0 | 0 |
Change in Payables | 726K | 2.44M | 4.09M | 60K | 818K | 2.37M | -7.58M | 1.81M | 6.04M | 4.46M |
Cash from Investing | -346K | -13.42M | -66.66M | -100.12M | -294.14M | -461.34M | 71.84M | 185.01M | -121.44M | 28.92M |
Capital Expenditures | -346K | -13.12M | -12.52M | -16.36M | -46.81M | -48.95M | -33.73M | -8.95M | -14.95M | -14.11M |
CapEx % of Revenue | - | - | 69544.44% | 68154.17% | 90.29% | 80.35% | 8.93% | 14.08% | 10.7% | 10.67% |
Acquisitions | 0 | 0 | 0 | 83.77M | 620K | 412.38M | 0 | 0 | -78K | -78K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -300K | 0 | -83.77M | 0 | -412.38M | 0 | 0 | 254.75M | 255.15M |
Cash from Financing | 4.98M | 179.73M | 41.28M | 322.32M | 756.14M | 111.59M | 276.45M | 7.74M | 478.05M | 101.28M |
Debt Issued (Net) | 0 | 0 | 5.71M | 1.7M | -2.12M | -2.29M | -2.25M | -485K | 0 | 93.07M |
Equity Issued (Net) | 4.98M | 179.72M | 37.9M | 319.53M | 757.45M | 108.26M | 270.17M | 8.22M | 478.05M | 6.45M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 10K | -2.34M | 1.1M | 810K | 5.62M | 8.53M | 0 | 0 | 1.75M |
Net Change in Cash | 1.93M▲ 0% | 146M▲ 7461.1% | -97.38M▼ 166.7% | 126.46M▲ 229.9% | 395.73M▲ 212.9% | -327.22M▼ 182.7% | 199.09M▲ 160.8% | -154.5M▼ 177.6% | 11.51M▲ 107.4% | -239.57M▲ 0% |
Free Cash Flow | -3.05M▲ 0% | -33.42M▼ 994.7% | -84.52M▼ 152.9% | -112.1M▼ 32.6% | -113.08M▼ 0.9% | -26.42M▲ 76.6% | -182.93M▼ 592.3% | -356.19M▼ 94.7% | -360.05M▼ 1.1% | -383.84M▲ 0% |
FCF Margin % | - | - | -469561.11% | -467075% | -218.11% | -43.37% | -48.43% | -560.77% | -257.65% | -290.19% |
FCF Growth % | - | -994.73% | -152.89% | -32.63% | -0.88% | 76.63% | -592.28% | -94.72% | -1.08% | -6.34% |
FCF per Share | -0.24 | -0.95 | -1.65 | -2.40 | -1.76 | -0.38 | -2.37 | -4.33 | -3.64 | -3.72 |
FCF Conversion (FCF/Net Income) | 0.31x | 0.18x | 0.92x | 0.49x | 0.18x | -0.08x | 1.13x | 0.92x | 4.31x | 5.90x |
Interest Paid | 0 | 0 | 187K | 0 | 567K | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BEAM Key Ratios
Beam Therapeutics Inc. (BEAM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -177.53% | -66.67% | -112.32% | -69.13% | -37.06% | -15.46% | -43.94% | -8.11% | -5.89% |
Return on Invested Capital (ROIC) | - | -136.57% | -69.63% | -97.24% | -46.41% | -18.94% | -46.83% | -31.11% | -27.64% |
Gross Margin | - | -303338.89% | -429812.5% | -347.75% | -411.48% | 100% | -478.67% | 84.05% | -64.2% |
Net Margin | - | -435144.44% | -810800% | -714.91% | -474.54% | -35.09% | -593.13% | -57.24% | -49.17% |
Debt / Equity | - | 0.31x | 0.44x | 0.18x | 0.24x | 0.18x | 0.22x | 0.24x | 0.13x |
Interest Coverage | - | -401.89x | - | - | - | - | - | -0.83x | 1.08x |
FCF Conversion | 0.18x | 0.92x | 0.49x | 0.18x | -0.08x | 1.13x | 0.92x | 4.31x | 5.90x |
Revenue Growth | - | - | 33.33% | 215916.67% | 17.51% | 520.01% | -83.18% | 120.01% | 108.05% |
Related:BEAM Dividend History·BEAM Revenue History·BEAM Price History·BEAM P/E History·BEAM Financial Ratios·BEAM Institutional Holders
BEAM SEC Filings & Documents
Beam Therapeutics Inc. (BEAM) SEC filings — annual & quarterly reports (10-K, 10-Q)
BEAM Frequently Asked Questions
Beam Therapeutics Inc. (BEAM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Beam Therapeutics Inc. (BEAM) reported $132.3M in revenue for fiscal year 2025.
Beam Therapeutics Inc. (BEAM) grew revenue by 120.0% over the past year. This is strong growth.
Beam Therapeutics Inc. (BEAM) reported a net loss of $65.0M for fiscal year 2025.
Dividend & Returns
Beam Therapeutics Inc. (BEAM) has a return on equity (ROE) of -8.1%. Negative ROE indicates the company is unprofitable.
Beam Therapeutics Inc. (BEAM) had negative free cash flow of $383.8M in fiscal year 2025, likely due to heavy capital investments.